
|Articles|June 15, 2011
Julian Upton
<>
Advertisement
Julian Upton serves as European Editor for Pharm Exec and as Editor of its digital sister publication, Pharm Exec Global Digest. Julian first joined Advanstar Communications in 1998 and has worked in various editorial capacities for the company. Outside Advanstar, he has edited business magazines on topics ranging from healthcare to finance and defence.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
The Evolving Relationship Between FDA and Biotech
4
What Kinds of Disruption are GLP-1s Expected to Face
5




